Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus ISOPAQUE 440.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus ISOPAQUE 440.
HYPAQUE-M,90% vs ISOPAQUE 440
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Iodinated radiocontrast agent that attenuates X-rays by increasing the iodine content in tissues, providing enhanced visualization of vasculature and organs during imaging procedures.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
Intravenous: 50-100 mL (22.05-44.1 g iodine) as a single dose for CT imaging; intra-arterial: 5-80 mL (2.2-35.28 g iodine) depending on procedure; dose is based on imaging requirements and patient weight.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. May be prolonged in renal impairment, correlating with creatinine clearance; dose adjustment not typically required for diagnostic procedures.
Renal: >95% unchanged; biliary/fecal: <5%
Primarily renal excretion via glomerular filtration. Approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Less than 5% is eliminated via biliary/fecal routes.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent